Instead, they should be considered alongside other variables such as eGFR, BMI and comorbidities to identify a specific pattern of diabetic kidney disease phenotype that may be more responsive to SGLT2 inhibitor therapy in terms of proteinuria reduction. The gene discussed is SLC5A2; the disease is diabetic kidney disease.